首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2075735

醣肽抗生素市場：按藥物、適應症、分銷管道和地區分類的規模、佔有率、前景和機會分析（2025-2032 年）

Glycopeptide Antibiotics Market, by Drug, by Disease Indication, by Distribution channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

醣肽抗生素市場預計到 2026 年將達到 33.793 億美元，預計到 2033 年將達到 45.681 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 4.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	33.793億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.40%	2033年市場規模預測：	45.681億美元

醣肽抗生素是一類透過抑制肽聚醣的合成來阻斷細菌細胞壁形成的抗生素。醣肽抗生素用於治療困難梭狀芽孢桿菌相關性腹瀉、心內膜炎、腸炎、住院期間或人工呼吸器期間發生的肺炎以及嚴重的皮膚和皮膚軟組織感染疾病。引起感染的細菌主要分為兩類：革蘭氏陽性菌和革蘭氏陰性菌。革蘭氏陽性菌缺乏覆蓋細胞壁的外膜，而革蘭氏陰性菌則具有覆蓋細胞壁的額外外膜。革蘭氏陰性菌對醣肽醣肽細胞壁，但醣肽對革蘭氏陽性菌引起的感染疾病有效。

此外，有些醣肽抗生素用於治療嚴重感染疾病時靜脈注射，而用於治療輕度感染疾病時則採用口服。由多重抗藥性革蘭氏陽性菌（如金黃色葡萄球菌、腸球菌屬和困難梭狀芽孢桿菌）引起的危及生命的感染疾病通常使用醣肽抗生素（GPAs）治療。這類抗生素的結構包含糖基化的環狀或多環狀非核醣體胜肽，最初是從植物和土壤細菌中分離出來的。這些抗生素透過抑制肽聚醣的合成來抑制易感微生物（主要是革蘭氏陽性球菌）細胞壁的形成。萬古黴素、Teicoplanin和拉莫拉寧是第一代醣肽抗生素的例子。奧利他班星、達巴班星和特拉萬星是第二代半合成醣肽抗生素的例子。

市場動態

在預測期內，醣肽抗生素產品上市和核准數量的增加預計將推動市場成長。例如，2019年6月，生物製藥公司ANI Pharmaceuticals, Inc.的萬古黴素鹽酸鹽口服溶液USP（250毫克/5毫升）的補充上市前申請獲得了美國食品藥物管理局（FDA）的批准，用於治療感染疾病。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球醣肽抗生素市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「全球醣肽抗生素市場」報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用全球醣肽抗生素市場分析中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第8章競爭情勢

ANI Pharmaceuticals, Inc.

Fresenius SE & Co. KGaA
Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc.
Melinta Therapeutics, Inc
Cumberland Pharmaceuticals Inc
Theravance Biopharma
Janssen Global Services, LLC
Bristol-Myers Squibb Company
GlaxoSmithKline plc.

第9章

參考
調查方法

簡介目錄

Product Code: CMI5455

Glycopeptide Antibiotics Market is estimated to be valued at USD 3,379.3 Mn in 2026 and is expected to reach USD 4,568.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3,379.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.40%	2033 Value Projection:	USD 4,568.1 Mn

Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.

Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.

Market Dynamics

Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global glycopeptide antibiotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market

Detailed Segmentation:

Global Glycopeptide Antibiotics Market, By Drug (Revenue, USD Mn, 2021 - 2033)
Vancocin
Orbactiv
Dalvance
Kimyrsa
Others
Global Glycopeptide Antibiotics Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
Clostridium difficile-associated Diarrhea
Endocarditis
Skin Structure Infections
Others
Global Glycopeptide Antibiotics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Glycopeptide Antibiotics Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - U.K.
  - Germany
  - France
  - Spain
  - Italy
  - Russia
  - Rest Of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
ANI Pharmaceuticals, Inc.*
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Fresenius SE & Co. KGaA
Pfizer Inc
Mylan N.V.
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc.
Melinta Therapeutics, Inc
Cumberland Pharmaceuticals Inc
Theravance Biopharma
Janssen Global Services, LLC
Bristol-Myers Squibb Company
GlaxoSmithKline plc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Glycopeptide Antibiotics Market, By Drug, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Vancocin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Orbactiv
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Dalvance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Kimyrsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

5. Global Glycopeptide Antibiotics Market, By Disease Indication, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Clostridium difficile-associated Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Endocarditis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Skin Structure Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Glycopeptide Antibiotics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

7. Global Glycopeptide Antibiotics Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
North America
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2021 - 2033, (US$ Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Competitive Snapshot
- ANI Pharmaceuticals, Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Fresenius SE & Co. KGaA
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Pfizer Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Hikma Pharmaceuticals plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Aurobindo Pharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
AbbVie Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Melinta Therapeutics, Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Cumberland Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theravance Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Janssen Global Services, LLC
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Bristol-Myers Squibb Company
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
GlaxoSmithKline plc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies